Evidence map›Paper›PMID 35935779›Full record

ArticleFrontiers in medicine2022

Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia.

Naniek Isnaini, Yan Mardian, Dewi Lokida, Fajar Budiono, Deni P Butar-Butar, Dona Arlinda, Gustiani Salim, Herman Kosasih, Wahyu Nawang Wulan, Jacqueline Perodin and 3 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Naniek IsnainiTangerang District Hospital, Tangerang, Indonesia.
Yan MardianIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
Dewi LokidaTangerang District Hospital, Tangerang, Indonesia.
Fajar BudionoTangerang District Hospital, Tangerang, Indonesia.
Deni P Butar-ButarIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
Dona ArlindaIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
Gustiani SalimIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
Herman KosasihIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
Wahyu Nawang WulanIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.
Jacqueline PerodinLeidos Biomedical Research, Frederick, MD, United States.
Aaron NealNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
H Clifford LaneNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Muhammad KaryanaIndonesia Research Partnership on Infectious Disease, Jakarta, Indonesia.

Funding

Pathogenesis, Treatment and Prevention of Emerging Infectious DiseasesZIAAI000936 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LANE, CLIFFORD · 2009 to 2025
$6.4M
6 · The paper itself

Abstract

Background: Reinfection with SARS-CoV-2 has been well documented, yet little is known about the degree of protection a previous infection provides against reinfection, especially against Variants of Concern (VOC). Case presentation: Here we describe a case of an unvaccinated 49-year-old man who experienced two sequential SARS-CoV-2 infections with two different variants, as evidenced by genomic sequencing. The first episode was caused by the Pango lineage B.1.466.2 and resulted in severe COVID-19 with 5 days in an intensive care unit (ICU). The second episode occurred approximately 6 months later, during the Delta surge in Indonesia. Genomic analysis showed that the second infection was caused by the Delta variant (Pango lineage B.1.617.2) and resulted in mild disease that did not require hospitalization. No SARS-CoV-2 nucleic acid was detected between the two episodes, but both binding and neutralizing antibodies to SARS-CoV-2 were detected prior to the reinfection, with the second infection leading to an increase in the levels of antibody. Conclusion: We confirmed that the patient experienced a reinfection instead of persistent viral shedding from the first infection based on epidemiological, clinical, serological, and genomic analyses. Our case supports the hypothesis that SARS-CoV-2 reinfection may occur once antibody titers decrease or following the emergence of a new variant. The milder presentation in the patient's second infection deserves further investigation to provide a clear picture of the role of post-infection immunity in altering the course of subsequent disease.

Indexed as

case reportCOVID-19Delta variantIndonesiareinfection

Identifiers

PMID35935779
PMCPMC9355687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.